Managers
PraxisIFM Group, a global financial services business listed on The International Stock Exchange (TISE), has received regulatory approval to complete the sale of its Fund Administration division to Sanne Group plc, in an all-cash deal totalling GBP54 million. This follows the original announcement of the sale in July.
As part of the terms of the transaction GBP5.5 million of the total consideration will now be held in escrow and is expected to be released in July 2022, subject to certain performance criteria.
Talis Capital has led a USD5.5 million seed funding round in Vinhealth, a digital health platform that improves the quality of life and outcomes of cancer patients, with participation from previous investors Playfair Capital and Ascension.
A number of angels also participated, including Keith Gibbs, former CEO of AXA PPP Healthcare; Pam Garside, partner at Newhealth; VOYAGERS Health-Tech Fund, led by David Rowan, founding editor of WIRED; David Giampaolo, healthcare entrepreneur and founder of PI Capital; Deepali Nangia, venture partner at Speedinvest and Atomico Angel; Faisal Mehmud, Vice President and former Medical Director of Bristol Myers Squibb; and KHP, a
Clessidra Private Equity SGR has acquired Viabizzuno, an Italian company specialising in the production of lighting projects in the premium/high-end sector for retail and residential clients, offices and hospitality, from 21 Invest.
Founded by Alessandro Benetton, 21 Invest acquired a controlling stake in Viabizzuno in 2011.
The investment marks the second transaction of Clessidra Capital Partners 4 fund, which held its first closing last June. Mario Nanni (Viabizzuno Style Director), Corrado Colli (CEO), Sebastiano Vasta (COO) and Simone Balsimelli (CFO) will support Clessidra in this transaction through the re-investment of a minority stake in the company and maintaining their
Growth investor Vitruvian Partners has a made a EUR45 million Series C investment in Enfuce, a European Card-as-a-Service (CaaS) platform for modern card issuing and processing.
The new capital will be used to further accelerate growth internationally as well as development of the Company’s technology platform.
Vitruvian Partners has previously invested in several successful financial services and payment companies including most recently Marqeta and TransferWise.
Goodhart Partners (Goodhart), an independent “multi-boutique” asset manager, has, through its Volunteer Park Capital Fund (Volunteer Park), taken a minority stake in Syntaxis, a provider of private credit in Central Europe.
Syntaxis’s leadership team has been working together for over 20 years, and the firm is currently investing its third private debt fund, Syntaxis New Europe Fund SCSp.
Seraphim Space Investment Trust (LSE: SSIT), a listed fund focused on Space Tech, has made a new USD25 million investment into ICEYE Oy (ICEYE), a specialist in synthetic aperture radar (SAR) satellite imaging technology.
Global investment bank Houlihan Lokey has completed the acquisition of GCA Corporation (GCA).
Following the acquisition of outstanding shares of GCA last month, the two companies will now operate as one firm under the Houlihan Lokey banner.
London Stock Exchange Group (LSEG) is to acquire Quantile Group Ltd, a provider of portfolio optimisation services for the global financial markets.
As part of LSEG, Quantile will operate as a standalone entity within the Post Trade division, reporting to Daniel Maguire, LSEG’s Group Head of Post Trade. Quantile will continue to be led by its CEO and co-founder, Andrew Williams.
In January 2021, Quantile received USD51 million in growth investment from Spectrum Equity, a growth equity firm focused on internet-enabled software and information services companies.
Mid-market private equity firm LDC has exited its investment in SRL Traffic Systems, a provider of portable and temporary traffic equipment, to 3i Infrastructure plc.
LDC backed the Cheshire-headquartered business in September 2019, investing GBP24 million to support the management team’s ambitious growth strategy. The exit generates a 5.7x money multiple for LDC on its original investment and an internal rate of return of 124 per cent.
Korea Investment Partners has led a EUR17.5 million Series B2 financing round in PDC*line Pharma, a clinical stage biotech company developing a new class of off-the-shelf lung cancer vaccine.
Less than two years after its EUR20M B1 round of fundraising, announced in January 2020, PDC*line Pharma has attracted new investors and secured a further capital increase of EUR11.8 million. In addition, the company has received a EUR5.7 million grant in repayable aid from the Walloon Region of Belgium, which has backed the company since its arrival in 2016. The company will therefore have raised a total of EUR37.5 million in
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
